BlueDop Medical

Peripheral Artery Disease (PAD) is a serious condition that can lead to severe complications, including limb loss, if not diagnosed early. Traditional tools like the Ankle-Brachial Index (ABI) have limitations, particularly in patients with diabetes or other conditions affecting blood vessels. A new publication published in the Journal of Vascular Surgery, shared by Dr. Patrick Kelly highlights the need for more accurate tools in assessing PAD. The use of BlueDop has shown: -           90% sensitivity and 96% specificity in detecting PAD across all patients. -           In diabetic patients, BVE reached an impressive 95.4% accuracy, far outperforming ABI’s 68.3%. Having a tool that provides reliable, real-time assessments is critical for early intervention and reducing complications. Read the full article to learn more: https://lnkd.in/eV-xjFT4 #VascularHealth #PAD #LowerLimbDisease #AccurateDiagnosis #MedicalResearch #BlueDop

As 2024 draws to a close, we’d like to acknowledge the vital work of tissue viability nurses, podiatrists, and district nurses in improving patient care. Your dedication to advancing vascular health and ensuring better outcomes for patients drives us at BlueDop to keep developing solutions that make your work more efficient and effective. Thank you for the impact you make every day on your patients and communities. #TissueViability #Nursing #Podiatry #HealthcareHeroes #BlueDop Society of Tissue Viability Royal College of Podiatry

2024 has been a year of progress, collaboration, and impact for BlueDop. From events like Stop the Pressure and our workshop at The University of Huddersfield, to the rollout of BlueDop technology in clinics across the country, we’ve seen incredible advancements in vascular health care. Thank you to our partners, clinicians, and teams for making these achievements possible. We’re proud of the work we’ve done together to improve patient outcomes and set new standards in vascular health. #YearInReview #BlueDop #VascularHealth #HealthcareInnovation

As we look back on 2024, we’re thankful for the opportunity to partner with healthcare professionals dedicated to improving patient outcomes. This year, BlueDop’s technology has supported clinicians in simplifying ABPI assessments and enhancing vascular health management. By prioritising patient comfort and clinical efficiency, we’ve taken steps together to make a meaningful difference in patient care. To everyone who has been part of this journey - thank you for your trust, collaboration, and commitment. As we move forward, we’re excited to continue innovating and supporting you in delivering the best care possible. Here’s to another year of advancing vascular health, together. #PatientCare #VascularHealth #ABPI #BlueDop #ThankYou

As the holiday season unfolds, we know how busy this time can be for healthcare professionals, especially with the added challenges of winter. At BlueDop, we’re here to help, offering technology that makes vascular assessments simpler, faster, and more reliable - so you can focus on what matters most. From all of us at BlueDop, we wish you a happy and healthy holiday season! #HappyHolidays #VascularHealth #BlueDop #PatientCare #HealthcareInnovation

We are pleased to share an article on "The value of accessible vascular assessment tools in diabetic foot disease: An audit of a tertiary level hospital" that was published in the Medical Independent. Authored by Astrid Codemo, this article explores the clinical impact of the BlueDop device in improving vascular assessments for patients with diabetic foot disease. Click here to read in full: https://lnkd.in/giGDqmFj The audit highlights the potential of accessible technologies like BlueDop to transform vascular health. Key findings include: - The BlueDop device, developed in 2010, enables a cuff-free measurement of the Ankle-Brachial Pressure Index (ABPI) by assessing arterial blood flow in the posterior tibial or dorsalis pedis artery. - In an audit of 23 diabetic patients with active foot ulceration, BlueDop assessments reduced waiting times to just 11 working days, compared with over 10 weeks for traditional vascular laboratory assessments. - The device demonstrated its ability to provide reliable readings even in cases of non-compressible vessels, addressing a key limitation of traditional ABPI methods. With its accessibility and efficiency, BlueDop is particularly suited to community healthcare settings, helping to bridge gaps in care and improve access to timely assessments. The findings underscore the importance of innovative diagnostic tools in reducing delays and improving outcomes for patients with diabetic foot disease. BlueDop is proud to play a part in setting new standards for vascular health. We would like to thank Astrid for her rigorous work in showcasing the clinical potential of the BlueDop device and for furthering the conversation around improving vascular care. Astrid’s efforts align with our mission to make vascular diagnostics more accessible, accurate, and patient-centred. At BlueDop, we remain committed to advancing vascular diagnostics, empowering healthcare providers, and improving patient outcomes worldwide. If you are interested in learning more about this study or how BlueDop is helping to shape the future of vascular health find out more at www.BlueDop.com #HealthcareInnovation #VascularHealth #DiabetesCare #MedicalResearch #PatientCentredCare

In 2024, Wounds UK released a new Best Practice Statement (BPS) to provide clear, evidence-based guidance for clinicians on assessing Ankle Brachial Pressure Index (ABPI) in patients with leg ulcers. This important document builds on the 2023 NICE diagnostic guidance regarding automated ABPI measurement devices. Developed by an expert working group chaired by Jacqui Fletcher OBE, and involving specialists in tissue viability, vascular care, and related fields, the BPS emphasises the importance of standardised ABPI testing practices within a holistic care framework. Key insights from the 2024 BPS include: - Diagnosing PAD and Compression Therapy: ABPI testing is critical for diagnosing Peripheral Arterial Disease (PAD) and safely initiating compression therapy for patients with leg ulcers. - Efficiency and Comfort with Automated Devices: Automated ABPI devices offer faster, easier, and more comfortable assessments compared to manual methods, streamlining care for patients and clinicians alike. - Improved Care Pathways: The BPS introduces a care pathway to efficiently integrate automated ABPI testing into practice, ensuring patients receive timely therapeutic compression. This guidance underscores the critical role of ABPI assessments in improving outcomes for patients with leg ulcers and highlights the need for training, accurate documentation, and holistic assessment to standardise and enhance care delivery. At BlueDop, our non-invasive, portable ABPI technology supports these goals by offering clinicians a faster, more accessible solution for vascular assessments. Together, we can help improve outcomes and set new standards in leg ulcer care. To learn more about BlueDop’s technology, visit www.BlueDop.co.uk #ABPI #PAD #VascularHealth #BlueDop #PatientCare #MedicalInnovation #WoundCare #HolisticHealth National Wound Care Strategy Programme (NWCSP)

Peripheral Artery Disease (PAD) affects millions worldwide, often remaining undiagnosed until it significantly impacts quality of life. Early detection is crucial for improving outcomes, particularly for at-risk patients. ABPI assessments are a key tool for early PAD detection, but traditional methods often face challenges like patient positioning and accessibility. BlueDop is changing that. With non-invasive, portable technology, BlueDop simplifies ABPI assessments - delivering fast, accurate, and reliable results. Patients benefit from greater comfort, and clinicians gain the tools they need to act sooner, improving care and outcomes. Discover how BlueDop is advancing PAD detection and transforming vascular health: www.BlueDop.co.uk #PADAwareness #ABPI #VascularHealth #BlueDop #PatientOutcomes

Thank you to everyone who attended Ross Robinson’s workshop at the Royal College of Podiatry Annual Meeting last Thursday! Your participation made it an engaging and insightful session, showcasing how BlueDop’s ankle cuffless technology enhances patient comfort and our visual triaging algorithm streamlines vascular assessments. We’re grateful for the thoughtful questions and feedback shared during the session; it’s these conversations that help drive meaningful progress in vascular health. We’d love to hear your key takeaways from the session - whether it was a new insight into the technology or its potential for your practice. Feel free to share your thoughts in the comments. #VascularHealth #ABPI #BlueDop #Podiatry #PatientCare #MedicalInnovation #RoyalCollegeofPodiatrists ALGEOS